Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anadys Pharmaceuticals has initiated dosing in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.
Subscribe to our email newsletter
The study will evaluate ANA598, the company’s direct-acting antiviral, in both treatment-naive patients and patients who have failed a prior course of HCV therapy with interferon and ribavirin.
The study will enroll approximately 275 patients.
The primary endpoint of the study will be sustained virological response 24 weeks after patients complete treatment.
The company expects to receive week 24 antiviral response results for both the treatment groups in the fourth quarter of 2011.